Viewing stories from January, 2025

Quarterly Activities Report & Appendix 4C

Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, today releases its Quarterly Activities Report and Appendix 4C for the quarter ended 31 December 2024 (Q2 FY25).

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.